[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catatonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catatonia":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,57,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100403241","blood-concentration-in-lorazepam-and-treatment-in-adult-catatonia-100403241",false,"NCT04530734","Blood Concentration in Lorazepam and Treatment in Adult Catatonia","PHARMAPREDICAT","Inclusion Criteria:\n\n* catatonia according DSM-5\n\nExclusion Criteria:\n\n* Subject is less than 18 years of age\n* Subject is pregnant at the time of the study\n* Subject\u002Flegal guardian unwilling to participate in the study","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Catatonia is a severe form of psychomotor disturbance with a heterogenous presentation. It affects approximately 10% of acute psychiatric inpatients. According to the fifth edition of DSM-5 the diagnosis of catatonia can be made when three or more symptoms from the twelve following are present : catalepsy, waxy flexibility, stupor, agitation, mutism, negativism, posturing, mannerisms, stereotypies, grimacing, echolalia, echopraxia. It can occur in various psychiatric diseases, including mood disorders or schizophrenia, but also in various non-psychiatric disorders \\[metabolic disturbances, viral infections (including HIV), typhoid fever, heat stroke, and autoimmune disease\\].\n\nBenzodiazepines, especially LORAZEPAM, are the most common initial treatment, with a remission rate of approximately 70-80 %, regardless of the cause or the clinical manifestations. This first line treatment is titrated gradually according to the therapeutic response over a few days up to 20-25 mg per day. Electroconvulsive therapy (ECT) is initiated on patients with catatonia who do not respond to benzodiazepines.\n\nInterestingly, pharmacogenetic variants can alter the metabolism of lorazepam (e.g., the UGT2B15 \\* 2 allele slows it down).\n\nThe main objective of this study is to assess the link between clinical response to lorazepam, residual plasma concentrations of lorazepam after 72 hours of fixed dosage, and the existence of genetic polymorphisms modifying the metabolism of lorazepam. Our hypothesis is that non-responding patients have lowered blood concentrations of lorazepam associated to a genetic profile of rapid metabolism. Evaluating the predictive factors of the response to treatment would allow early and precise identification of non-responder patients in order to adapt their first-line treatment.",[24],"Catatonia","RECRUITING","2026-05-20",{"date":28,"type":29},"2026-05-22","ACTUAL",{"date":31,"type":29},"2020-01-01",{"date":33,"type":20},"2027-01",{"name":35,"class":36},"University Hospital, Lille","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":37},"100617189","catatonic-syndrome-in-adult-patients-at-basurto-hospital-a-descriptive-study-of-incidence-comorbidity-and-short-term-outcomes-100617189","NCT07315386","Catatonic Syndrome in Adult Patients at Basurto Hospital: A Descriptive Study of Incidence, Comorbidity, and Short-Term Outcomes","Inclusion Criteria\n\n* Age ≥ 18 years at the time of hospital care.\n* Diagnosis of catatonic syndrome established according to DSM-5 criteria.\n* Patients attended at Basurto University Hospital in any clinical setting, including the Emergency Department or inpatient physical or psychiatric units.\n* Diagnosis made during the study period, from 1 January 2024 to 31 December 2025.\n* Catatonia of any etiology, including psychiatric, neurological, medical, metabolic, toxic, or autoimmune causes.\n* Provision of informed consent by the patient or their legal representative, when clinically feasible; deferred consent accepted in cases of acute catatonia.\n\nExclusion Criteria\n\n* Refusal to participate in the study by the patient or their legal representative.\n* Withdrawal of informed consent at any point during the study.",{"count":45,"type":20},40,"This study aims to assess the incidence, sociodemographic and clinical characteristics, treatment response, and short-term outcomes of adult patients with catatonic syndrome in the Bilbao area (Spain). Data will be collected from January 2024 to December 2025 from all patients aged 18 years or older diagnosed with catatonia of any etiology at Basurto University Hospital who provide informed consent to participate.",[24],"2026-05-11",{"date":50,"type":29},"2026-05-12",{"date":52,"type":29},"2024-01-01",{"date":54,"type":20},"2030-12-31",{"name":56,"class":36},"Beatriz Rodriguez Cabo",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":37},"100636101","optimizing-stimulation-parameters-for-electroconvulsive-therapy-100636101","NCT07561307","Optimizing Stimulation Parameters for Electroconvulsive Therapy","Parameter Refinement for ECT Stimulation and Titration Optimization","PRESTO","Inclusion Criteria:\n\n* Any patients being treated with electroconvulsive therapy at Pennsylvania Hospital who are willing and able to participate are eligible to be subjects in this study.\n\nExclusion Criteria:\n\n1. They are unwilling or unable to consent first to the SWEET COMBO protocol for optical monitoring during ECT\n2. Clinically significant psychiatric comorbidity as determined by clinical interview and in the opinion of the Investigator and clinical team would alter the risk\u002Fbenefit of the study\n3. History of poor response to ECT treatment in the opinion of the Investigator and clinical team that would alter the risk\u002Fbenefit of the study\n4. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may compromise, interfere with, limit, affect or reduce the:\n\n   1. subject's ability to participate safely in the study\n   2. integrity of the data or\n   3. subject's ability to complete the full duration of the study.",{"count":66,"type":20},64,"INTERVENTIONAL",[69],"NA","The goal of this clinical trial is to improve how electroconvulsive therapy (ECT) stimulation settings are chosen. Researchers will use real-time brain monitoring to measure both seizures and a recently identified brain event called cortical spreading depolarization (CSD).\n\nThe main questions it aims to answer are:\n\nWhat is the best way to increase ECT stimulation settings? How do different pulse settings affect the brain's response? Can certain settings produce CSD without causing a seizure?\n\nParticipants already receiving ECT as part of their care will take part. They will be assigned to one of two groups:\n\nIndex ECT group: Participants starting ECT will receive different standard titration approaches.\n\nMaintenance ECT group: Participants receiving ongoing ECT will undergo a brief, low-dose stimulation test before treatment.\n\nAll participants will be monitored using brain physiology (EEG and blood flow) and symptom scales during treatment.",[72,24],"Depression - Major Depressive Disorder",[74],"electroconvulsive therapy","NOT_YET_RECRUITING","2026-04-23",{"date":78,"type":29},"2026-05-01",{"date":80,"type":20},"2026-07-01",{"date":82,"type":20},"2030-06-30",{"name":84,"class":36},"University of Pennsylvania",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":67,"phases":95,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100566545","immunogenomic-analyses-of-pediatric-catatonia-100566545","NCT06656572","Immunogenomic Analyses of Pediatric Catatonia","Inclusion Criteria:\n\n* Individual in whom one of the following criteria is met:\n\n  1. Child\u002Fadolescent Ages 0-17 (2) with a diagnosis of catatonia.\n\n     OR\n  2. Biological parents of child\u002Fadolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed to be genetically related to a patient participant\n\nExclusion Criteria:\n\n* Child\u002Fadolescents patients who do not meet any of the inclusion criteria, or those who:\n\n  1. Already received any prior whole genome sequencing or exome sequencing.\n  2. Unable to approach the family or patient for enrollment.\n  3. Unable to obtain informed consent.\n  4. Family members are ineligible for participation in this study if:\n\n     1. They are known to not be genetically related to the child\u002Fadolescent patient participant","0 Years","17 Years",{"count":94,"type":20},120,[69],"Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 40 children and adolescents who are admitted to Rady Children's Hospital San Diego with a catatonia diagnosis. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve the ability to identify the cause of catatonia and impact care. The investigator also hopes to identify new genetic and\u002For autoimmune causes of catatonia that may inform new treatment for future patients.",[24],[99,100],"Genomics","Pediatric","2024-11-12",{"date":103,"type":29},"2024-11-14",{"date":105,"type":20},"2024-12-01",{"date":107,"type":20},"2030-09-01",{"name":109,"class":36},"Rady Pediatric Genomics & Systems Medicine Institute"]